Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Zoledronic Acid Doses in Chinese Postmenopausal Osteoporosis
NCT04719650Phase 4Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of zoledronic acid in postmenopausal osteoporosis (4 arms), sponsored by Peking University Third Hospital. Primary endpoints: Concentration of Zoledronic acid at 36 months, Maximum concentration of Zoledronic acid and 10 more. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04719650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719650.